163 related articles for article (PubMed ID: 9294833)
1. Nephrotoxicity of amphotericin B is attenuated by solubilizing with lipid emulsion.
Dórea EL; Yu L; De Castro I; Campos SB; Ori M; Vaccari EM; Lacaz Cda S; Seguro AC
J Am Soc Nephrol; 1997 Sep; 8(9):1415-22. PubMed ID: 9294833
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D deficiency is a potential risk factor for lipid Amphotericin B nephrotoxicity.
Ferreira D; de Bragança AC; Volpini RA; Shimizu MHM; Gois PHF; Girardi ACC; Seguro AC; Canale D
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007567. PubMed ID: 31295336
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.
Hossain MA; Maesaki S; Razzaque MS; Tomono K; Taguchi T; Kohno S
J Antimicrob Chemother; 2000 Aug; 46(2):263-8. PubMed ID: 10933650
[TBL] [Abstract][Full Text] [Related]
4. Comparison of conventional and lipid emulsion formulations of amphotericin B: Pharmacokinetics and toxicokinetics in dogs.
Nieto J; Alvar J; Rodríguez C; San Andrés MI; San Andrés MD; González F
Res Vet Sci; 2018 Apr; 117():125-132. PubMed ID: 29272720
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin is less nephrotoxic than amphotericin B in vitro and predominantly damages distal renal tubular cells.
Wegner B; Baer P; Gauer S; Oremek G; Hauser IA; Geiger H
Nephrol Dial Transplant; 2005 Oct; 20(10):2071-9. PubMed ID: 15998654
[TBL] [Abstract][Full Text] [Related]
6. Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents.
Zager RA; Bredl CR; Schimpf BA
Kidney Int; 1992 Jun; 41(6):1588-94. PubMed ID: 1501413
[TBL] [Abstract][Full Text] [Related]
7. Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture.
Joly V; Saint-Julien L; Carbon C; Yeni P
J Pharmacol Exp Ther; 1990 Oct; 255(1):17-22. PubMed ID: 2213553
[TBL] [Abstract][Full Text] [Related]
8. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
[TBL] [Abstract][Full Text] [Related]
9. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Falci DR; da Rosa FB; Pasqualotto AC
Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
[TBL] [Abstract][Full Text] [Related]
10. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules.
Bernardo JF; Murakami S; Branch RA; Sabra R
Nephron; 1995; 70(2):235-41. PubMed ID: 7566310
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of amphotericin B and liposomal amphotericin B on inflammatory cells in vitro.
Baronti R; Masini E; Bacciottini L; Mannaioni PF
Inflamm Res; 2002 May; 51(5):259-64. PubMed ID: 12056514
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.
Nath CE; Shaw PJ; Gunning R; McLachlan AJ; Earl JW
Antimicrob Agents Chemother; 1999 Jun; 43(6):1417-23. PubMed ID: 10348763
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Renal Toxicity of Monomeric Amphotericin B in Rats after a Multiple Dose Regimen.
Kang JY; Gao J; Shin DH; Alvarez C; Zhong W; Kwon GS
Pharm Nanotechnol; 2016; 4(1):16-23. PubMed ID: 27774409
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.
López-Sánchez A; Pérez-Cantero A; Torrado-Salmerón C; Martin-Vicente A; García-Herrero V; González-Nicolás MÁ; Lázaro A; Tejedor A; Torrado-Santiago S; García-Rodríguez JJ; Capilla J; Torrado S
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760126
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
Kaur K; Kumar P; Kush P
Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
[TBL] [Abstract][Full Text] [Related]
17. Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses.
Saint-Julien L; Joly V; Seman M; Carbon C; Yeni P
Antimicrob Agents Chemother; 1992 Dec; 36(12):2722-8. PubMed ID: 1482139
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS).
Fukui H; Koike T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Sep; 263(1-2):51-60. PubMed ID: 12954180
[TBL] [Abstract][Full Text] [Related]
19. A novel delivery system for amphotericin B with lipid nano-sphere (LNS).
Fukui H; Koike T; Saheki A; Sonoke S; Seki J
Int J Pharm; 2003 Oct; 265(1-2):37-45. PubMed ID: 14522116
[TBL] [Abstract][Full Text] [Related]
20. Must we really fear toxicity of conventional amphotericin B in oncological patients?
Mayer J; Doubek M; Vorlìcek J
Support Care Cancer; 1999 Jan; 7(1):51-5. PubMed ID: 9926976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
